Pharmacyclics Inc., of Sunnyvale, Calif., disclosed results for the fourth quarter and for 2014, recording in the first full year of Imbruvica (ibrutinib) sales total revenue of $730 million, driven by U.S. net product revenue of $492 million for 2014, compared to U.S. net product revenue of $14 million for the prior year.